Optimizing use of TKIs in CML

Hagop Kantarjian, MD
Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), according to the keynote presenter at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Studies have indicated that long-term survival rates are similar whether CML patients receive frontline treatment with imatinib or second-generation TKIs. However, the newer TKIs pose a higher risk of uncommon toxicities, said Hagop Kantarjian, MD, a professor at MD Anderson Cancer Center in Houston, Texas, who gave the meeting’s keynote speech. [Read Article]

Genomic findings may predict outcomes in MPN patients

Essential thrombocythemia
New research suggests genomic characteristics of patients with myeloproliferative neoplasms (MPNs) can predict clinical outcomes. Investigators defined eight genomic subgroups of MPNs, each with distinct clinical features, including event-free survival, risk of leukemic transformation, and blood counts. Jacob Grinfeld, MD, of the University of Cambridge in the U.K., and his colleagues described these findings in The New England Journal of Medicine. [Read Article]

Inhibitor receives orphan designation for PTCL

T-cell lymphoma
Image by Michael Bonert
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL). Cerdulatinib is an oral Syk/JAK inhibitor being developed by Portola Pharmaceuticals, Inc. Preclinical data have suggested an important role for Syk and JAK in PTCL tumor survival, and cerdulatinib is currently under evaluation in a phase 2a study of patients with PTCL and other non-Hodgkin lymphomas. [Read Article]